[Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].
Fiche publication
Date publication
janvier 2018
Journal
Biologie aujourd'hui
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François
Tous les auteurs :
Ghiringhelli F
Lien Pubmed
Résumé
Recent advances in cancer immunotherapy with the development of anti-PD1/PD-L1 antibodies are revolutionizing cancer care. Nevertheless, the efficacy of these treatments in monotherapy is limited to a subpopulation representing about 25-30% of patients in most indications. The development of new strategies is based on combinations between standard treatments (cytotoxic chemotherapy and radiotherapy) and immunotherapy in order to find synergistic combinations.
Référence
Biol Aujourdhui. 2018 ;212(3-4):77-79